Jalen Hurts’s blood-clot diagnosis raises a hard question for the NFL: when a team’s medical staff clears a star player to compete, who ensures that decision puts the player’s health first?
The Eagles quarterback was diagnosed with a superficial blood clot in his left calf before the October 11 game against the Jaguars in London. He was cleared to play. Follow-up testing later showed the condition had progressed to deep vein thrombosis and bilateral pulmonary emboli, meaning clots had reached both lungs. Hurts is expected to miss the rest of the season. [1][2]
There is another part of the timeline worth considering: Hurts reportedly took two flights, each lasting approximately seven hours, within three days. Extended periods of immobility during air travel are a recognized risk factor for blood clots, particularly when someone already has a clotting condition. This makes the travel schedule an important part of the medical circumstances surrounding his clearance. It raises additional questions about whether the potential risks of flying and playing were adequately considered when evaluating his condition.
That progression does not automatically mean the Eagles were negligent. But the circumstances raise real questions about medical judgment and whether the league’s system provides enough independent oversight when player health and competitive interests collide.
Eagles and NFL Defend Decision
According to the Eagles, Hurts first sought treatment on October 8, and a London ultrasound on October 10 identified the superficial clot. The team says its medical staff and London physicians determined he could safely play, with a follow-up ultrasound recommended within 72 hours. That exam showed the clot had progressed. [1] On October 19, the team and Hurts’s agent, Nicole Lynn, announced the more serious diagnosis. [2]
The NFL backed the team’s handling of the matter. On October 20, Chief Medical Officer Dr. Allen Sills called the care conservative and patient-focused, argued that a worsening outcome does not mean the original decisions were flawed, and rejected the idea that outside pressure would push physicians to put players at risk. [3]
These statements deserve consideration, but their sources matter. The Eagles have an interest in defending their medical staff, and the league has an interest in preserving confidence in its safety system. That doesn’t make their explanations false, but it means they can’t substitute for an independent examination of the facts.
The Conflict-of-Interest Problem
Team physicians can owe competing obligations to the athletes they treat and the organizations that employ them. A 2016 Hastings Center Report article examined this dual loyalty, noting that teams and players share an interest in health, but diverge when availability affects competition. The authors proposed separating the clinicians who treat players from those who evaluate them for teams. [4]
That concern is sharpest with a franchise quarterback. Hurts’s value to the Eagles should never factor into whether he is medically cleared. The NFL-NFLPA Collective Bargaining Agreement addresses player medical care in Article 39, including requirements for team physicians and consultants. [5] The open question is whether that structure provides enough independence and accountability once a decision is challenged.
What Accountability Looks Like
On October 20, the NFLPA called for a full investigation, saying it was unaware of any league review and that the league had earlier indicated it didn’t plan one. [6] The next day, Commissioner Roger Goodell said the NFL welcomed a review, while maintaining that its protocols were followed. [7] On October 25, the league and the union announced they would review the matter together. [8] That’s a meaningful step, but reporting described the effort as still in its planning stage, so its scope and whether the findings will be made public remain open questions.
Independent safeguards do exist elsewhere in the league. The concussion return-to-play protocol, for example, requires clearance from an independent neurological consultant in addition to the team physician. [9] It doesn’t apply to blood clots, but it shows independent review is workable in professional football.
The joint review should examine what information the London doctors had, the reasoning behind clearing Hurts, whether the risks associated with his travel schedule were considered, the recommended follow-up care, and the communications among the team, outside physicians, and league officials.
Player Safety Must Be the Priority
Much remains unknown, and a worsening condition alone does not establish malpractice. The goal isn’t to assign blame before the evidence is in. It’s to determine whether the process adequately protected Hurts and whether serious conditions outside injury-specific protocols need clearer safeguards.
Football depends on athletes accepting physical risk, but that doesn’t relieve organizations of the duty to take their health seriously. When a player is cleared after a serious diagnosis, the question shouldn’t end with whether the team followed its own process. It should ask whether that process was independent enough to protect the athlete whose health was on the line.
Sources
[1] Philadelphia Eagles, “Statement from the Philadelphia Eagles on QB Jalen Hurts” (October 15, 2026).
[2] Philadelphia Eagles, “Eagles and Jalen Hurts’ Agent Nicole Lynn Provide an Update on QB Jalen Hurts” (October 19, 2026).
[3] NFL.com, “NFL Supports Eagles’ Treatment of QB Jalen Hurts’ Medical Situation” (October 20, 2026).
[4] I. Glenn Cohen, Holly Fernandez Lynch & Christopher R. Deubert, “A Proposal to Address NFL Club Doctors’ Conflicts of Interest and to Promote Player Trust,” Hastings Center Report (2016).
[5] NFL and NFL Players Association, Collective Bargaining Agreement, Article 39: Players’ Rights to Medical Care and Treatment (2020).
[6] ESPN, “NFLPA Demands Full Investigation into Hurts’ Medical Care” (October 21, 2026).
[7] Associated Press/NFL.com, “Commissioner Roger Goodell Says NFL Welcomes Review of How Eagles Handled Jalen Hurts’ Blood Clots” (October 21, 2026).
[8] Yardbarker, “NFL reverses course on Jalen Hurts blood clot case after NFLPA pushback” (October 25, 2026).
[9] NFL.com, “NFL Health and Safety Fact Sheet,” describing the league’s independent medical safeguards and concussion return-to-participation protocol.
All players when injured should look to their protections under their local Workers’ Compensation Law, Those laws may give players the right to choose their own medical provider, not under the control of the team for medical advice.